BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Sickle Cell Disease Association of America Inc. - ECPv4.6.26//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Sickle Cell Disease Association of America Inc.
X-ORIGINAL-URL:https://www.sicklecelldisease.org
X-WR-CALDESC:Events for Sickle Cell Disease Association of America Inc.
BEGIN:VEVENT
DTSTART;TZID=UTC:20190618T143000
DTEND;TZID=UTC:20190618T153000
DTSTAMP:20250104T024028
CREATED:20190612T174712Z
LAST-MODIFIED:20190612T174712Z
UID:2994-1560868200-1560871800@www.sicklecelldisease.org
SUMMARY:Congressional Briefing on Progress in Sickle Cell Disease Treatment & Policy Implications
DESCRIPTION:TUESDAY\, JUNE 18\, 2019 | 2:30 – 3:30 PM\nDIRKSEN SENATE OFFICE BUILDING\, ROOM G50\nRSVP: Betsy Foss-Campbell\, bfoss@asgct.org\n\nJoin us for updates on Gene therapy approaches presented by prominent scientists in the field\nHow policymakers can support the development of treatment options for sickle cell disease\nSPEAKERS\nTim Scott\, United States Senator\nFrancesca Cook\, MPH\, Government Relations Committee member\, ASGCT; Senior Director\, Pricing and Market Access\, REGENXBIO\nJulie Kanter\, MD\, Director of Adult Sickle Cell Program; Associate Professor of Hematology and Oncology\, University of Alabama at Birmingham\nPunam Malik\, MD\, Professor of Pediatrics\, Marjorie Johnson Chair of Gene and Cell Therapy\, Director\, Cincinnati Comprehensive Sickle Cell Center; Cancer and Blood Disease Institute\, Cincinnati Children’s Hospital\nRodrick Murray\, Patient advocate providing a personal story on gene therapy’s value for treating sickle cell disease\nMatthew Porteus\, MD\, PhD\, Professor of Pediatrics (Stem Cell Transplantation)\, Stanford University\nDavid Williams\, MD\, Senior Vice President and Chief Scientific Officer\, Boston Children’s Hospital; Chief\, Hematology/Oncology\, Boston Children’s Hospital; President\, Dana-Farber/Boston Children’s Cancer and Blood Disorders Center; Leland Fikes Professor of Pediatrics\, Harvard Medical School\nHow can policymakers help support the development of gene therapies for sickle cell disease? \n\nSupport the need for robust NIH research funding\nSupport appropriations to the sickle cell disease prevention and treatment program and implementation of new surveillance and screening authorities passed in 2018\nEnable novel payment models for approved gene therapies\n\nHosted in partnership with the Pediatric Hospital Sickle Cell Disease Collaborative and\n \n
URL:https://www.sicklecelldisease.org/event/congressional-briefing-on-progress-in-sickle-cell-disease-treatment-policy-implications/
ATTACH;FMTTYPE=image/jpeg:https://www.sicklecelldisease.org/wp-content/uploads/2019/06/capitol_hill_lg.jpg
END:VEVENT
END:VCALENDAR